Outcomes of Flecainide Therapy in Rheumatic Atrial Arrhythmias: A Study on Effectiveness and Safety
DOI:
https://doi.org/10.63682/jns.v14i17S.5705Keywords:
Atrial arrhythmias, Flecainide, Atrial fibrillation, Sinus rhythm, Acute rheumatic fever.Abstract
Background: Rheumatic heart disease (RHD) results from damage to heart valves following an episode of acute rheumatic fever (ARF). This study aimed to evaluate the efficacy of flecainide in treating rheumatic atrial arrhythmias, assessing the percentage of patients who maintained sinus rhythm and identifying any adverse drug reactions (ADRs).
Method: A prospective observational study was conducted over six months at Care Hospitals, Banjara Hills, Hyderabad; involving 30 patients aged 18 to 65 with various rheumatic atrial arrhythmias. Exclusions included those with structural or ischemic heart disease and individuals unwilling to participate.
Results: Results indicated that rheumatic atrial arrhythmias were present in 20 patients (66.6%). The highest incidence occurred in the 50-60 age group (36.9%), with a predominance of females (63.4%). The mean age of participants was 53.8 ± 0.71 years. Among the 30 patients, 25 had atrial fibrillation; flecainide was effective in 17 patients (68%) and ineffective in 8 (32%). For the 5 patients with atrial flutter, 3 (60%) demonstrated a positive response to treatment. The most commonly prescribed dosage for maintaining sinus rhythm was 50 mg.
Conclusion: In conclusion, rheumatic atrial arrhythmias are more prevalent among females and the middle-aged population. Flecainide was effective in 66.6% of cases, particularly in atrial fibrillation, with initial dosing starting at 50 mg/day, which could be increased to 150 mg/day based on clinical response.
Downloads
Metrics
References
Christopher H, Beth C. Rheumatic Heart disease. National Library of Medicine 2015; 4(5): 492.
Padmavati S. Rheumatic fever and rheumatic heart disease in developing countries, Bull World Health Organ 1958; 56:543.
Rheumatic fever and rheumatic heart disease, World Health Organization1988; 9:764.
Padmavati S. Rheumatic fever and rheumatic heart disease in India. In Progress in cardiology 2001; 53(1): 35.
Padmavati S. Present status of rheumatic fever and rheumatic heart disease in India. Indian Heart 1995; 47:395–398.
Sharma M, Saxena A, Kothari SS. Acute rheumatic fever in children: experience from a cardiac centre. Indian Heart, 1999; 51:652.
Mishra TK, Rath PK, Mohanty NK. Juvenile chronic RHD: our decade long experience. Indian Heart, 1999; 51:653.
Ahamed MZ, Jayasree P, Narayanan SN. Rheumatic chorea in children—a study of prevalence of clinical and echocardiographic valvular involvement. Indian Heart 1999; 51:694.
Bahi VK, Raju BS, Panja M. Non-coronary cardiac interventions. Second report by the non-coronary cardiac interventions registry of India. Cardiological Society of India, 1998; 50(1): 99-104.
B. Vuyyala, S. K. Deivasigamani and L. M. R. Thakkalapally. Anxiolytic Potentiality of Tamarindus indica Flowers. Indian Journal of Pharmaceutical Sciences 2022; 84 (6):1-10.
Zoni-Berisso, M; Lercari, F; Carazza, T; Domenicucci, S. "Epidemiology of atrial fibrillation: European perspective". Clinical epidemiology 2004; 6: 213–20.
Bhardwaj R. Atrial fibrillation in a tertiary care institute – A prospective study. Indian Heart 2012;64:476 8
Vijay Bohra, Gautam Sharma, RajnishJuneja. Burden of Atrial Fibrillation in India.Journal of the Practice of Cardiovascular Sciences 2015; 1: 231-232.
Nadeem MA, Wassem T, Mahmood K, Imran SF, Khan AH. Differences in clinical profile and echocardiographic finding in patient with valvular and non valvular origin of atrial fibrillation. 1999;5:44-48
Balakrishna Vuyyala, D Senthil Kumar, Thakkalapally Lakshmi. In-vivo Assessment of Tranquilizer activity of various extracts of Cajanus cajan leaves in Mice. Advances in Pharmacology and Pharmacy 2021; 9(4): 87-93.
Brooks, S., Metzner, A., Wohlmuth, P., Lin, T., Wissner, Tilz, R., Ouyang, F. Insights into ablation of persistent atrial fibrillation: Lessons from 6-year clinical outcomes [Abstract]. Journal of Cardiovascular Electrophysiology 2018; 29(2), 257–263.
Regmi PR, Pandey MR. Rheumatic fever and rheumatic heart disease in school children of Kathmandu city. Indian Heart, 1997;49:518–520.
Wilson D. Cardiological Society of India Reuse of disposables in the catheterization laboratory—report of the committee appointed by the Cardiological Society of India. Indian Heart, 1997; 49:329–331.
Vlietstra RE. Interventional cardiology worldwide. J Intervent Cardiol, 1995; 8:17–18.
Balakrishna Vuyyala, D Senthil Kumar, Thakkalapally Lakshmi. Evaluation of Anxiolytic potential of various extracts of Caesalpinia pulcherrima leaves. Research Journal of Pharmacy and Technology. 2021; 14(11):5625-8.
Howlett, P. J., Hatch, F. S., Alexeenko, V., Jabr, R. I., Latham, E. W., & Fry, C. H. Diagnosing paroxysmal atrial fibrillation. BioMed Research International, 2015; 9(10):267.
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, Jr, J. C., Yancy, C. W. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation 2014; 130, e199–e267.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
